Insilico Medicine

Executive Summary

Insilico Medicine is a clinical-stage AI-driven drug discovery company leveraging its proprietary Pharma.AI platform to accelerate target identification and molecule design. Founded in 2014 and headquartered in Hong Kong, the company integrates generative AI and deep learning to streamline early-stage drug development, targeting areas such as oncology, fibrosis, and immunology. With a growing pipeline of internal programs and strategic collaborations with major pharmaceutical firms, Insilico aims to reduce the time and cost of bringing novel therapeutics to patients. Its platform-based approach positions it as a leader in AI-enabled drug discovery, with potential to transform how new medicines are developed.

Upcoming Catalysts (preview)

• H2 2026Phase 2 topline data for lead IPF candidate55% success
• TBDNew strategic partnership with top-10 pharma70% success
• Q1 2027IND filing for next-generation oncology program80% success